Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib by Kiana Keyvanjah et al.
Keyvanjah et al. Journal of Translational Medicine 2012, 10:165
http://www.translational-medicine.com/content/10/1/165RESEARCH Open AccessSoluble KIT correlates with clinical outcome in
patients with metastatic breast cancer treated
with sunitinib
Kiana Keyvanjah1,2,3*, Samuel E DePrimo1,2,4, Charles S Harmon1,2,5, Xin Huang1, Kenneth A Kern1
and William Carley1,2,6Abstract
Background: Sunitinib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor
receptors, and stem cell factor receptor (KIT). The ability of soluble (s)KIT, VEGF-A, sVEGFR-2, and sVEGFR-3 to predict
clinical outcome was analyzed in 61 patients with previously treated metastatic breast cancer (MBC) in a phase II
study of sunitinib monotherapy (ClinicalTrials.gov NCT00078000).
Methods: Plasma concentrations of soluble proteins were measured at baseline and during treatment with
sunitinib 50 mg/day (4 weeks on treatment, 2 weeks off treatment). Baseline concentrations and maximal percent
change during the first two treatment cycles were stratified by median values and evaluated for correlation with
median time to tumor progression (TTP) and overall survival (OS). This latter fixed time period was chosen to avoid
bias accruing from patients who were on study for longer periods of time.
Results: TTP was significantly longer in patients having median or higher maximal percent sKIT change compared
with patients with less than the median change (21.7 vs. 7.9 weeks; p < 0.0001). Similarly, OS was significantly longer
in patients having median or higher sKIT change versus less than the median change (53.7 vs. 25.7 weeks;
p = 0.018). Significant prolongation of OS (62.6 vs. 32.3 weeks; p = 0.032), but not TTP, was observed in patients with
a median or higher maximal percent VEGF-A change compared with less than the median change. Maximal
percent change of sVEGFR-2 or sVEGFR-3 concentrations and baseline concentrations of all four proteins were not
predictive of clinical outcome.
Conclusions: This exploratory analysis suggests that changes in sKIT and possibly VEGF-A early during sunitinib
treatment may be predictive of clinical outcome in MBC.
Keywords: Sunitinib, Metastatic breast cancer, BiomarkersBackground
Prognostic and predictive biomarkers have long been
sought to aid in optimizing therapy and elucidating
mechanisms involved in metastatic breast cancer (MBC).
An ideal biomarker should be quantifiable early during
disease or treatment and be capable of providing evi-
dence for underlying disease mechanisms that may then
serve as a therapeutic target. However, the high degree
of heterogeneity in MBC has made study of this disease* Correspondence: kkeyvanj@gmail.com
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reproduction in any medium, provided the orparticularly challenging, and, although many biomarkers
have been assessed in clinical trials, few have advanced
into clinical practice [1].
Sunitinib malate (SUTENTW; Pfizer, Inc.) is an orally
administered, small-molecule tyrosine kinase inhibitor with
targets that include vascular endothelial growth factor re-
ceptor (VEGFR)-1, -2, and -3; platelet-derived growth fac-
tor receptor (PDGFR)-α and -β; and stem cell factor
receptor (KIT) [2-4]. Sunitinib is approved multinationally
for the treatment of metastatic renal cell carcinoma;
gastrointestinal stromal tumor (GIST) after disease pro-
gression on, or intolerance to, imatinib treatment; and
metastatic pancreatic neuroendocrine tumor.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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implicated in the pathogenesis of breast cancer: for
example, expression of VEGF-A, PDGF-AB, and
PDGFR-β has been associated with poor prognosis
[5-7]. Expression of KIT, a member of the PDGFR
subfamily, has also been detected in breast cancer
cells with a prevalence of between 1% and 25%
[8-14]. A lack of standardized procedures may ex-
plain the observed variation in expression of KIT,
and while its actual prevalence (and the clinical
relevance of its presence in individual breast carcin-
omas) remains to be determined, it has been sug-
gested that KIT, as part of a broader array of
markers, could assist in the appropriate classification
of breast cancer patients, and their subsequent as-
signment to therapy [14]. Elucidation of the path-
ways responsible for breast cancer would aid
identification of patient subpopulations that might
benefit from specific targeted therapies.
Results of a previously published phase II trial [15] sug-
gested that single-agent sunitinib had antitumor activity in
patients with heavily pretreated MBC (N=64): an objective
response rate (ORR) of 11% was achieved and 5% of
patients had stable disease (SD) for≥6 months.
Additionally, the ORR in patients with triple-negative
tumors (i.e. those negative for estrogen receptor [ER], pro-
gesterone receptor, and HER2; n=20) was 15%.
In this earlier work, a limited analysis of soluble (s)
biomarkers (sKIT, VEGF-A, sVEGFR-2, and sVEGFR-3)
was undertaken [15]. Results showed that plasma bio-
marker concentrations changed in response to sunitinib
treatment and suggested that these changes correlated
with clinical outcomes. The current analysis was under-
taken to explore the latter results in more detail using
methods distinct from those published previously.
Methods
Patients
The study involved female patients ≥ 18 years of age with
confirmed breast adenocarcinoma not amenable to sur-
gery, radiation, or curative therapies. Patients had to
have had previous treatment with an anthracycline as
well as a taxane, and all chemotherapy and radiation
treatments must have been completed at least 3 weeks
prior to enrollment in the study. Other eligibility criteria
were described previously [15].
The study was performed in accordance with the
International Conference on Harmonisation Good
Clinical Practice guidelines, the Declaration of Helsinki,
and applicable local regulatory requirements and laws.
The study was approved by the institutional review
board or independent ethics committee of each partici-
pating center. All patients gave written, informed con-
sent prior to enrollment.Study design and treatment administration
This was an open-label, single-arm, phase II study con-
ducted at eight centers in the United States. The primary
end point was ORR. Secondary end points included time
to tumor progression (TTP), overall survival (OS), safety
and tolerability, and an exploration of potential soluble
plasma biomarkers of response (sKIT, VEGF-A,
sVEGFR-2, and sVEGFR-3). Each treatment cycle con-
sisted of 4 weeks of treatment with sunitinib 50 mg
administered orally once daily followed by 2 weeks off
treatment (Schedule 4/2) [15].
Study procedures
Baseline evaluations have been described previously [15].
Response Evaluation Criteria in Solid Tumors were used
to determine progression of disease and response to
treatment [16]. Plasma samples were taken for analysis
of soluble protein biomarkers before sunitinib treatment
on study days 1, 14, and 28 of the first treatment cycle,
on days 1 and 28 of subsequent cycles, and at the end of
treatment. Samples were collected in heparinized tubes.
Plasma levels of the biomarkers were analyzed with vali-
dated enzyme-linked immunosorbent assay kits or kit
components (R&D Systems) in compliance with Good
Laboratory Practice guidelines as described previously
[17]. Lower limits of quantification for the assays were
31.1, 6.4, 78.1, and 156 pg/mL for sKIT, VEGF-A,
sVEGFR-2, and sVEGFR-3, respectively.
Statistical analysis
Plasma concentrations of soluble proteins were evaluated
independently, and descriptive statistics were calculated
for each biomarker at each time point. The maximal
change in the concentration of each plasma biomarker
observed during the first two treatment cycles was calcu-
lated for each patient. This fixed time period was chosen
to avoid bias accruing from patients who were on study
for longer periods of time. Patients who had fewer than
two plasma biomarker concentration measurements that
were quantifiable within the assay range during the first
two treatment cycles (three patients for sKIT, VEGF-A,
and sVEGFR-2 measurements and nine patients for
sVEGFR-3 measurements, of 64 patients in the study)
were therefore excluded from the analysis. The maximal
change was calculated as a percentage of the maximal
change from cycle 1 day 1 (C1D1) until the end of treat-
ment in cycle 2 (C2D28) as follows [18]:
maximumconcentrationminimum concentrationð Þ  100
maximum concentration
Medians of this value for each protein were used as
the cutpoints for stratification of patients into two
groups, which were then evaluated for correlation with
the efficacy end points TTP and OS. Efficacy
Table 1 Patient demographic and clinical characteristics
Characteristic Sunitinib (N = 64)
Median (range) age, years 52 (36–70)
ECOG performance status, n (%)
0 24 (38)
1 40 (63)




Receptor status, n (%)
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were stratified based on baseline biomarker concentra-
tions, using median values to determine the cutpoints.
Time-to-event analyses were performed using the
Kaplan-Meier method; results were compared using the
Cox proportional hazards model, the Mantel-Haenszel
method, and the log-rank test. Univariate and multivari-
ate analyses were performed using the Cox proportional
hazards regression model with S+ v8.0 (TIBCO Spot-
fire). Other analyses were performed using GraphPad
Prism 5.1 (GraphPad Software) and Microsoft Office




Metastatic sites, n (%)




Pleural effusion 17 (27)
Local recurrence 16 (25)Results
Patient characteristics
In total, 64 patients were enrolled in the study [15]. Pa-
tient characteristics at baseline are summarized in
Table 1. Tumors were ER-negative in 42% of patients
(n = 27), HER2-positive in 19% of patients (n = 12), and
triple-negative in 31% of patients (n = 20). All patients
had received prior chemotherapy, and all received at
least one dose of sunitinib. Details of sunitinib dosing
and efficacy and safety outcomes in this study have been
reported previously [15].Skin 14 (22)
Primary tumor 4 (6)
Prior systemic therapy,* n (%) 64 (100)
Anthracycline + taxane+ other 60 (94)
Anthracycline + taxane 1 (2)
Anthracycline + other 2 (3)
Other 1 (2)
Adapted from Burstein HJ, et al.: J Clin Oncol 2008, 26(11):1810–1816 [15] with
permission. © 2008 American Society of Clinical Oncology. All rights reserved.
ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR,
progesterone receptor. *Eight patients (13%) also received prior trastuzumab
treatment.Effect of sunitinib treatment on plasma biomarker levels
As reported previously, significant changes (p < 0.00005)
in mean plasma levels were observed for all four bio-
markers within the first cycle of sunitinib treatment
[15]. Concentrations of sKIT decreased as treatment
progressed (for up to eight cycles) irrespective of off-
treatment periods (Figure 1A). VEGF-A concentrations
generally increased during the 4-week periods on treat-
ment, while sVEGFR-2 and sVEGFR-3 concentrations
decreased during the on-treatment periods (Figure 1B-
D). Levels of each of these latter three markers
returned to near-baseline concentrations at the end of
the 2-week off-treatment periods.
As reported previously, C2D28 was found to be the
time point by which mean/median reductions in sKIT
levels relative to baseline reached approximately 50%,
the cutpoint used in the earlier analysis [15]. C2D28 was
also the time point by which the greatest change in
plasma concentrations was determined to occur across
all four biomarkers by visual inspection of the graphs in
Figure 1. Therefore, the median of the maximal percent
changes observed from C1D1 to C2D28 was used as the
cutpoint for stratification of the study population into
two groups (Table 2); these values were 48.6%, 89.4%,
55.8%, and 52.8% for sKIT, VEGF-A, sVEGFR-2, and
sVEGFR-3, respectively. Maximal percent changes for in-
dividual patients are shown in Figure 2. In patients with
triple-negative disease (highlighted in Figure 2), nodistinct pattern was apparent with regard to changes in
biomarker levels.Correlation between early changes in plasma biomarker
levels and clinical outcome
Sixty-one patients had two or more plasma sKIT mea-
surements during the first two treatment cycles. Median
TTP was 21.7 weeks in patients having a maximal per-
cent sKIT change equivalent to the median or higher
(n = 31) compared with a median TTP of 7.9 weeks in
patients with less than the median maximal sKIT change
(n = 30; hazard ratio [HR], 5.99; 95% confidence interval
[CI], 3.06-11.7; p < 0.0001; Table 2; Figure 3A). Patients
with sKIT changes equivalent to the median or higher
had a median OS of 53.7 weeks compared with
25.7 weeks in patients with less than the median change
Figure 1 Plasma protein concentrations in individual patients during treatment with sunitinib. (A) sKIT. (B) VEGF-A. (C) sVEGFR-2. (D)
sVEGFR-3. sKIT, soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor.
Table 2 Associations between maximal percent changes in biomarker concentrations or baseline biomarker
concentrations and efficacy endpoints
Biomarker Median value
(range)
Endpoint < Median value ≥ Median value HR* (95% CI) p
n Median time to
event, weeks
n Median time to
event, weeks
Median maximal percent change in biomarker concentration from C1D1 to C2D28
sKIT 48.6% (−) TTP 30 7.9 31 21.7 5.99 (3.06-11.7) < 0.0001
OS 25.7 53.7 2.33 (1.16-4.70) 0.018
VEGF-A 89.4% (−) TTP 30 9.9 31 10.3 1.75 (0.99-3.09) 0.054
OS 32.3 62.6 2.12 (1.06-4.23) 0.032
sVEGFR-2 55.8% (−) TTP 30 10.1 31 10.2 1.07 (0.62-1.85) 0.81
OS 36.0 53.7 1.52 (0.76-3.02) 0.24
sVEGFR-3 52.8% (−) TTP 27 10.1 28 11.0 1.40 (0.77-2.52) 0.27
OS 51.6 52.7 1.98 (0.79-4.96) 0.15
Median baseline biomarker concentration
sKIT 70 ng/mL (26–113) TTP 28 10.6 28 10.1 1.08 (0.60-1.96) 0.80
OS 37.4 45.1 1.13 (0.55-2.35) 0.74
VEGF-A 53 pg/mL (14–709) TTP 25 10.1 26 10.2 0.71 (0.38-1.33) 0.29
OS Not reached 33.0 0.55 (0.25-1.22) 0.14
sVEGFR-2 11 ng/mL (4–15) TTP 28 10.3 28 10.1 0.98 (0.54-1.76) 0.94
OS 37.4 62.6 1.19 (0.57-2.46) 0.65
sVEGFR-3 68 ng/mL (25–152) TTP 28 10.1 28 10.2 0.97 (0.54-1.75) 0.93
OS 37.4 53.7 1.43 (0.68-2.98) 0.35
C, cycle; CI, confidence interval; D, day; HR, hazard ratio; OS, overall survival; sKIT, soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; TTP,
time to tumor progression; VEGF, vascular endothelial growth factor.
*HR > 1 favors the groups with values≥median value.
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Figure 2 Maximal percent change in plasma protein concentration from C1D1 to C2D28 by patient. (A) sKIT. (B) VEGF-A. (C) sVEGFR-2. (D)
sVEGFR-3. Light gray bars denote patients with triple-negative disease. Broken horizontal lines denote median values for each protein. C, cycle; D,
day; sKIT, soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; VEGF, vascular endothelial growth factor.
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Figure 3B).
Sixty-one patients had two or more plasma VEGF-A
measurements during the first two treatment cycles.
Patients with a maximal percent VEGF-A change
equivalent to the median or higher (n = 31) had a me-
dian TTP of 10.3 weeks compared with 9.9 weeks in
patients with less than the median change in VEGF-A
(n = 30; HR, 1.75; 95% CI, 0.99-3.09; p = 0.054; Table 2;
Figure 3C). Similarly, in the group with a VEGF-A
change equivalent to the median or higher, patients had
a median OS of 62.6 weeks compared with 32.3 weeks
in the patients with less than the median change in
VEGF-A (HR, 2.12; 95% CI, 1.06-4.23; p = 0.032; Table 2;
Figure 3D).
No statistically significant differences in TTP or OS
were observed between groups when patients were strati-
fied based on the maximal percent change in plasma
sVEGFR-2 or sVEGFR-3 concentrations (Table 2).
In addition to changes in plasma biomarker concentra-
tions, we evaluated the relationships between baseline
demographic and disease characteristics (including age,race, hormone status, and Eastern Cooperative Oncology
Group performance status) and clinical outcomes in uni-
variate and multivariate analyses (Table 3). Among these,
a significant association with TTP was only found for
race. In multivariate analysis using models combining
sKIT change and race with or without VEGF-A change,
greater sKIT change (evaluated either as a categorical or
a continuous variable) was highly predictive of improved
TTP (p < 0.0001), as was non-white race (p = 0.0055),
while VEGF-A change (categorical variable) did not
show a statistically significant association. In univariate
analysis of OS, only age showed a significant correlation
among baseline characteristics and was included in
multivariate models with sKIT with or without VEGF-A
change. Greater sKIT change (either as a categorical or
continuous variable) and age < 65 (noting that this group
represented 98% of patients) were significantly asso-
ciated with improved OS in the multivariate analyses
(p = 0.0085, < 0.0001, and = 0.0045, respectively), while
greater VEGF-A change (categorical variable) and age
evaluated as a continuous variable showed marginally
significant associations (both p = 0.047).
Figure 3 TTP and OS by median maximal percent change in plasma protein concentration through C2D28. (A) TTP by sKIT concentration.
(B) OS by sKIT concentration. (C) TTP by VEGF-A concentration. (D) OS by VEGF-A concentration. C, cycle; D, day; OS, overall survival; sKIT, soluble
KIT; TTP, time to tumor progression; VEGF, vascular endothelial growth factor.
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and clinical outcome
When patients were stratified based on median baseline
concentrations, no statistically significant differences in
TTP or OS were detected between the groups of
patients with baseline concentrations above or below the
median values (Table 2).
Discussion
We performed a detailed analysis of the ability of four
plasma proteins (sKIT, VEGF-A, sVEGFR-2, and
sVEGFR-3) to predict clinical outcome with sunitinib in
patients with previously treated MBC. Biomarker cut-
points were assessed using two different parameters: per-
cent maximal change in biomarker concentration during
the first two treatment cycles and median baseline con-
centrations. Among these analyses, changes in the levels
of sKIT during treatment showed the strongest associa-
tions with clinical outcome, with greater reductions insKIT levels being predictive of improved TTP and OS.
Notably, of the seven patients in the study who had con-
firmed partial responses, six had changes in sKIT levels
that were greater than or equal to the median value (the
seventh had fewer than two quantifiable plasma samples
within the first two treatment cycles and was unevaluable
for this analysis; data not shown). Greater increases in
VEGF-A levels showed a trend towards an association
with improved TTP and a statistically significant associ-
ation with improved OS. These results were confirmed in
multivariate analyses, in which changes in sKIT levels
were shown to be a statistically significant predictor of
both TTP and OS, and VEGF-A change, a marginally sig-
nificant predictor of OS. Baseline concentrations of all
four proteins using median values to determine cutpoints
were not found to be predictive of clinical outcome.
Determination of appropriate cutpoints for stratifying
patients in exploratory biomarker analyses is often em-
pirical and arbitrary in nature. Previous analyses of the
Table 3 Univariate and multivariate analysis of relationships between baseline patient characteristics or early changes
in biomarker concentrations and clinical outcome
n* TTP OS
HR† 95% CI p HR† 95% CI p
Univariate analysis
Age (< 65 vs. ≥ 65 years) 59/5 1.19 0.43-3.33 0.74 3.09 1.17-8.16 0.023
Race (white vs. non-white) 52/11 0.39 0.18-0.86 0.019 0.67 0.26-1.72 0.40
ECOG performance status (0 vs. ≥ 1) 24/40 1.20 0.70-2.04 0.53 1.58 0.78-3.21 0.21
ER (+ vs. −) 37/27 1.14 0.66-1.96 0.64 1.60 0.80-3.20 0.18
PgR (+ vs. −) 26/35 0.88 0.50-1.54 0.65 1.60 0.81-3.16 0.17
HER2 (+ vs. −) 12/48 0.74 0.38-1.45 0.38 0.70 0.29-1.69 0.43
Triple-negative (yes vs. no) 20/43 0.99 0.56-1.76 0.97 0.67 0.31-1.42 0.29
Baseline sKIT (continuous{) 61 1.00 0.97-1.02 0.82 0.99 0.96-1.02 0.48
Baseline VEGF-A (continuous{) 63 1.11 0.98-1.27 0.11 1.10 0.95-1.28 0.22
Baseline sVEGFR-2 (continuous{) 62 0.99 0.89-1.10 0.83 0.91 0.80-1.03 0.15
Baseline sVEGFR-3 (continuous{) 54 1.00 0.99-1.01 0.77 1.00 0.99-1.01 0.97
sKIT change (≥ 48.6% vs. < 48.6%) 30/31 4.36 2.38-7.97 < 0.0001 2.28 1.13-4.60 0.022
VEGF-A change (≥ 89.4% vs. < 89.4%) 31/30 1.71 0.99-2.96 0.054 2.25 1.09-4.65 0.029
sVEGFR-2 change (≥ 55.8% vs. < 55.8%) 31/30 1.14 0.67-1.94 0.63 1.37 0.68-2.74 0.37
sVEGFR-3 change (≥ 52.8% vs. < 52.8%) 28/27 1.39 0.79-2.45 0.26 1.66 0.79-3.52 0.18
sKIT change (continuous{) 61 0.93 0.91-0.96 < 0.0001 0.94 0.92-0.97 < 0.0001
VEGF-A change (continuous{) 61 0.99 0.97-1.01 0.21 0.98 0.96-1.00 0.042
sVEGFR-2 change (continuous{) 61 1.00 0.98-1.02 0.95 0.99 0.97-1.01 0.45
sVEGFR-3 change (continuous{) 55 0.99 0.98-1.01 0.38 0.98 0.96-1.00 0.051
Multivariate analysis of factors showing significance in univariate analysis}
Model using categorical variables
Age (< 65 vs. ≥ 65 years) − − − − 4.45 1.59-12.48 0.0045
Race (white vs. non-white) − 0.30 0.12-0.70 0.0055 − − −
sKIT change (≥ 48.6% vs. < 48.6%) − 4.75 2.48-9.08 < 0.0001 2.69 1.29-5.64 0.0085
VEGF-A change (≥ 89.4% vs. < 89.4%) − 1.62 0.93-2.80 0.086 2.10 1.01-4.34 0.047
Model using continuous variables
Age (continuous{) − − − − 1.05 1.00-1.09 0.047
Race (white vs. non-white) − 0.25 0.11-0.61 0.0021 − − −
sKIT change (continuous{) − 0.92 0.90-0.95 < 0.0001 0.94 0.92-0.97 < 0.0001
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HR, hazard ratio; OS, overall survival; PgR, progesterone receptor; sKIT,
soluble KIT; sVEGFR, soluble vascular endothelial growth factor receptor; TTP, time to tumor progression; VEGF, vascular endothelial growth factor.
*Number of patients analyzed in univariate analysis (for categorical variables, numbers for both groups are shown).
†For categorical variables, HR > 1 favors the first category and HR< 1 favors the second category; for continuous variables, HR > 1 favors the value when it
decreases and HR< 1 favors the value when it increases.
{Modeled as a continuous variable.
}n= 60 for the TTP models because race was unknown in one patient, and n= 61 for the OS models.
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data at each time point relative to its value at baseline,
and although statistically significant correlations were
also shown between decreases in plasma concentrations
of sKIT (decreases by ≥ 50% at the start or end of the last
treatment cycle relative to baseline) and improved clin-
ical outcomes [15], the methodology employed assumed
that intrapatient variability was low, and that the stand-
ard errors between samples taken at different time
points were similar. The use of percent maximal change
in biomarker concentrations in the current analysis hasthe advantage of effectively circumventing assumptions
about intrapatient variability [18].
The results obtained in the present analysis, together
with those obtained from earlier analyses of the same
dataset [15], are suggestive of early changes in sKIT
levels being a biomarker of clinical outcome with suniti-
nib in MBC. However, in breast cancer, the role of KIT
remains unclear. Studies comparing levels of both KIT
mRNA and protein with breast tumors and normal
breast tissue have yielded conflicting results (reviewed
in reference [19]). A more recent report, however,
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concluded that KIT was expressed in 15% of breast can-
cer patients and was a prognostic indicator of poor clin-
ical outcome [14]. Activating KIT mutations have not so
far been reported in breast cancer, although research to
date has utilized patient series of limited size [10]. More-
over, clinical results obtained with sunitinib in phase III
studies and with imatinib (also a KIT inhibitor) in phase
II studies utilizing broad populations of patients with
HER2-negative advanced breast cancer (without selec-
tion for any biomarker), whether alone or in combin-
ation with cytotoxic chemotherapies, have been
disappointing [20-26]. However, all of these sunitinib
studies in advanced breast cancer utilized sunitinib at
37.5 mg on a continuous daily dosing (CDD) schedule,
rather than 50 mg/day on Schedule 4/2 as in the present
study. Additionally, single-agent sunitinib (at 37.5 mg on
the CDD schedule) was recently found to be less effect-
ive than standard-of-care chemotherapies in patients
with previously treated advanced triple-negative breast
cancer (TNBC) [27], a type of breast cancer thought to
be associated with higher frequencies of KIT expression
[9,28,29]. Although partial responses were observed in
three of 20 (15%) patients with tumors that were triple-
negative in the present study [15], a clear correlation did
not appear to exist between sKIT changes and TNBC
per se (Figure 2A). KIT overexpression has also been
reported to occur more frequently in ductal carcinomas
compared with other breast cancer histologies [11].
While all tumor responses in the present study occurred
in patients whose tumors had a ductal histology, the
tumors of most patients in the study overall were classi-
fied as ductal (84%) [15], precluding any conclusions
being drawn about relationships between histologic type
and the effects of sunitinib on the biomarkers measured.
Given the heterogeneity of breast cancer overall and of
sub-types such as TNBC in particular, a prospective
biomarker-driven study would be required to definitely
assess the role of KIT and the utility of sKIT in deter-
mining the outcomes of breast cancer patients treated
with KIT inhibitors.
In contrast to the results obtained with sKIT changes
during sunitinib treatment, baseline sKIT concentrations
were not found to be predictive of TTP or OS in our
analyses. A similar lack of correlation between baseline
sKIT levels and clinical outcomes was reported in GIST
[30], a tumor type in which activating mutations yielding
constitutively active KIT proteins occur in approximately
80% of tumors [31]. In clinical trials of patients with
GIST, treatment with either sunitinib (both at 50 mg/
day on Schedule 4/2 and at 37.5 mg on the CDD sched-
ule) or imatinib was found to be highly efficacious, sug-
gesting that KIT inhibition was critical for tumor
control [32-34]. In addition, a decline in plasma sKITlevels after two cycles of sunitinib treatment has been
shown to function as a potential surrogate marker for
TTP in GIST [30]. That report noted that a relatively
large component of physiologic sKIT is likely to be unre-
lated to the tumor at baseline, given the levels of sKIT
found in healthy individuals [35].
The limited associations seen in the present analyses be-
tween greater changes in VEGF-A levels and improved
outcomes were not noted in the earlier analysis of this
dataset [15]. However, with increases in circulating
VEGF-A being a well-known pharmacodynamic effect of
sunitinib treatment [15,17], an association between greater
pharmacodynamic changes and improved outcomes is not
unexpected. Such a potentially predictive association has
also been reported in sunitinib-treated renal cell carcin-
oma [17,36] and hepatocellular carcinoma [37], but not
GIST [38,39]. Possible associations between VEGF-A
levels and clinical outcomes have also been evaluated with
other antiangiogenic agents. For example, baseline levels
of plasma VEGF-A were recently reported to be a poten-
tial biomarker of improved clinical outcomes with the
anti-VEGF monoclonal antibody bevacizumab in patients
with advanced gastric cancer [40]. Additionally, high base-
line levels of VEGF-A have been associated with poor
prognosis in breast cancer and other tumor types [5,41].
In our analyses, it may be worth noting that there was a
trend towards an association between low baseline
VEGF-A levels and improved outcomes (Tables 2 and 3),
although this did not reach statistical significance.
The earlier analysis of this dataset noted a trend to-
wards an association between decreases of sVEGFR-3
levels of ≥20% at the start of cycle 2 (or the last treat-
ment cycle) and longer OS (p = 0.07) [15]. In the present
analysis, no association between changes in sVEGFR-3
levels and clinical outcome was observed.
The current analyses were limited by several factors.
One such limitation was their retrospective nature, which
restricts clinical interpretation of the data. Small sample
size was another limitation: as in many clinical trials, the
study was powered to support the primary endpoint
(ORR), with biomarkers evaluated only as a secondary ob-
jective. Additionally, the study utilized a relatively unse-
lected patient population as described previously. Finally,
because this was a single-arm, non-comparative study, it
was unable to distinguish whether any biomarkers identi-
fied were prognostic or predictive in nature.
Conclusions
The current exploratory analysis suggests that changes in
sKIT and possibly VEGF-A observed during early treat-
ment cycles may serve as predictive markers for clinical
outcome (TTP and OS) with sunitinib in this patient
population. The inability to consistently demonstrate
broad clinical benefit with sunitinib and other targeted
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lations of patients with advanced breast cancer in recently
reported phase III studies highlights the urgent need to
identify biomarkers of efficacy to identify specific subsets
of patients that do benefit. The associations between
changes in sKIT and clinical outcome described in this
study suggest that better characterization of breast cancer
subtypes expressing KIT and elucidation of its role in
control of tumor growth may be worthwhile. Our results
and methodology may also be applicable to the develop-
ment of other KIT inhibitors in this heterogeneous
patient population.Abbreviations
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